Accuray's Precision Treatment System Gains Approval in China, Expanding Cancer Care Options
Portfolio Pulse from Benzinga Newsdesk
Accuray Incorporated (NASDAQ:ARAY) has received approval from the Chinese National Medical Products Administration for its Precision Treatment Planning System. This approval allows the system to be used with the CNNC-Accuray joint venture Tomo® C radiation therapy system, expanding cancer care options in China.
June 12, 2024 | 11:39 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Accuray's Precision Treatment Planning System has been approved by the Chinese National Medical Products Administration, allowing it to be used with the CNNC-Accuray joint venture Tomo® C radiation therapy system. This approval expands cancer care options in China.
The approval by the Chinese National Medical Products Administration is a significant regulatory milestone for Accuray. It allows the company to expand its market presence in China, potentially increasing sales and revenue. The news is likely to have a positive short-term impact on ARAY's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100